Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review
GD Lopaschuk, S Verma - Basic to Translational Science, 2020 - jacc.org
Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …
Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models
Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …
challenges facing cardiovascular medicine today. Despite being the most common form of …
Periodontal disease, systemic inflammation and the risk of cardiovascular disease
EF Carrizales-Sepúlveda, A Ordaz-Farías… - Heart, Lung and …, 2018 - Elsevier
Periodontal and cardiovascular disease are both major health issues. Poor oral health has
long been associated with the development of systemic diseases, with the typical example …
long been associated with the development of systemic diseases, with the typical example …
Inflammation and metabolic cardiomyopathy
K Nishida, K Otsu - Cardiovascular research, 2017 - academic.oup.com
Excessive feeding is associated with an increase in the incidence of chronic metabolic
diseases, such as obesity, insulin resistance, and type 2 diabetes. Metabolic disturbance …
diseases, such as obesity, insulin resistance, and type 2 diabetes. Metabolic disturbance …
[HTML][HTML] NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases
A Fiordelisi, G Iaccarino, C Morisco, E Coscioni… - International journal of …, 2019 - mdpi.com
Inflammation is a key mechanism of cardiovascular diseases. It is an essential component of
atherosclerosis and a significant risk factor for the development of cardiovascular events. In …
atherosclerosis and a significant risk factor for the development of cardiovascular events. In …
Iron deficiency in heart failure
Iron deficiency is a major heart failure co‐morbidity present in about 50% of patients with
stable heart failure irrespective of the left ventricular function. Along with compromise of daily …
stable heart failure irrespective of the left ventricular function. Along with compromise of daily …
Immunometabolic mechanisms of heart failure with preserved ejection fraction
GG Schiattarella, P Alcaide, G Condorelli… - Nature cardiovascular …, 2022 - nature.com
Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence worldwide,
already accounting for at least half of all cases of heart failure. As most patients with HFpEF …
already accounting for at least half of all cases of heart failure. As most patients with HFpEF …
Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure
EC Perin, KM Borow, TD Henry, FO Mendelsohn… - Journal of the American …, 2023 - jacc.org
Abstract Background Mesenchymal precursor cells (MPCs) are allogeneic, immunoselected
cells with anti-inflammatory properties that could improve outcomes in heart failure with …
cells with anti-inflammatory properties that could improve outcomes in heart failure with …
[HTML][HTML] The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases
S Zhazykbayeva, S Pabel, A Mügge, S Sossalla… - Biophysical …, 2020 - Springer
The complex physiological signal transduction networks that respond to the dual challenges
of inflammatory and oxidative stress are major factors that promote the development of …
of inflammatory and oxidative stress are major factors that promote the development of …
Iron and heart failure: diagnosis, therapies, and future directions
K Ghafourian, JS Shapiro, L Goodman… - Basic to Translational …, 2020 - jacc.org
To date, 3 clinical trials have shown symptomatic benefit from the use of intravenous (IV) iron
in patients with heart failure (HF) with low serum iron. This has led to recommendations in …
in patients with heart failure (HF) with low serum iron. This has led to recommendations in …